


EU market players with links to polluting pharma companies in India and China.

French drugs giant **Sanofi** has links to dirty production via its Czech subsidiary **Zentiva**, which sources the antibiotic Ciprofloxacin from **Neuland Pharmaceuticals** - an Indian pharma company that has been implicated in unlawful manufacturing discharges.



Supply chain research found **NHS** Trusts to be sourcing **Aurobindo** products directly, or through other brands under its ownership, including **Milpharm**, **Arrow Generics**, and Aurobindo's own brand.

Pfizer has long-standing ties with polluting pharma companies in India and China. In addition to sourcing antibiotic products from **Aurobindo** in India, it has joint venture agreements with **Zhejiang-Hisun** and **Zhejiang Hisoar** in China - two companies hit by recent U.S. import bans on their products, including antibiotics. Its subsidiary **Hospira** has been marred by a series of GMP scandals, most recently resulting in an EU import suspension on 6 antibiotic products in August 2016.

Aurobindo Unit VII in Polepally, near Hyderabad, directly supply antibiotics to **McKesson**, a San Francisco-based pharma distribution giant which delivers one-third of all medications used daily in North America. These are sold under McKesson's **NorthStar Rx** brand across the United States. **McKesson** also has strong links to U.S. pharmacy giant **CVS Health**, its single largest customer, to which it sold \$40 billion worth of products in the year ending March 2016. Following its acquisition of the German pharmacy conglomerate **Celesio** in 2014, McKesson is also a major player in the EU, and owns the **Lloyds Pharmacy** chain (the second biggest pharmacy in the UK), and leading French pharmacies, **OCP** and **Pharmactiv**.

Polluting Chinese companies have links to the EU and U.S. markets, either directly or through preliminary export to India. Italy's **Fresenius Kabi Anti-Infectives** imports the antibiotics Ampicillin and Benzylpenicillin from **CSPC Zhongnuo**, a Chinese pharma company subject to a U.S. import ban.

Polluting or non-GMP-compliant Chinese companies with EU/US market links



India's **Parabolic Drugs** - a company that itself has a string of manufacturing violations to its name - imports the antibiotic Ceftriaxone from **CSPC Zhongnuo** before exporting on to **Midas Pharma** in Greece.

Polluting Indian companies producing antibiotics for the European and US markets.



DRUG RESISTANT BACTERIA FOUND

GLOBAL ANTIBIOTICS SUPPLY CHAIN